James Sapirstein, R.Ph.


Mr. Sapirstein, who most recently served as chief executive officer and board member for ContraVir Pharmaceuticals, Inc. (NASD: CTRV) has close to 35 years of pharmaceutical industry experience. His expertise spans such areas as drug development and commercialization, having participated in 23 product launches, six of which were global launches that he led. He is also credited with leading numerous business development transactions over the course of his career. Prior to ContraVir, Mr. Sapirstein was chief executive officer of Alliqua Therapeutics. He has also previously served as the founding chief executive officer of Tobira Therapeutics, as well as executive vice president, metabolic and endocrinology for Serono Laboratories. Mr. Sapirstein’s earlier career included a number of senior level positions in the area of marketing and commercialization, including global marketing team lead for Viread (tenofovir) while at Gilead Sciences and director of international marketing of the infectious disease division at Bristol Myers Squibb. Mr. Sapirstein is currently the chairman of BioNJ and also serves on the emerging companies board of Biotechnology Innovation Organization (BIO).

Mr. Sapirstein earned a bachelor’s degree in pharmacy from Rutgers University and holds an MBA degree in management from Fairleigh Dickinson University.